Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer, BioNTech Asks FDA to Expand Use of Their Covid-19 Vaccine to Adolescents

04/09/2021 | 02:59pm EDT

By Jared S. Hopkins

Pfizer Inc. and BioNTech SE asked U.S. health regulators to allow their Covid-19 vaccine to be given to adolescents, which could make the shots available to kids in the coming weeks.

The companies said Friday that they asked the U.S. Food and Drug Administration to extend their shot's use to children 12 years and older. The companies also said they planned to make similar requests to regulators in other countries.

The Pfizer-BioNTech vaccine is currently authorized in the U.S. for people 16 years and older. Shots from Moderna Inc. and Johnson & Johnson are authorized in the U.S. for use in adults 18 years and older.

The FDA expects to take a few weeks to review the request, a person familiar with the matter said. The agency doesn't plan, the person said, to ask a panel of outside experts to review the submission, as the agency did before first authorizing the shot in December.

Health authorities say it will be important to vaccinate children to protect them from the virus and help reach the communitywide immunity needed to move past the pandemic, known as herd immunity.

Children are at lower risk of becoming infected with the coronavirus than adults and when they become sick tend to experience milder symptoms. Some can get seriously ill, and some can also spread the virus.

The vaccine from Pfizer and BioNTech was 100% effective in protecting against symptomatic disease in a study of more than 2,200 kids 12 years and older, the companies said last month. There weren't any safety concerns.

Researchers found the shot to be 100% effective after observing 18 cases of Covid-19 in children who had received a placebo, compared with no cases in the group that got vaccinated. Researchers added they didn't see any severe cases, deaths or hospitalizations.

Researchers also said vaccinated youths generated high levels of antibodies, which play a key role in the immune response, similar to those seen in subjects 16 to 25 years of age in the vaccine's pivotal trial.

The Pfizer-BioNTech vaccine is given in two doses three weeks apart. Children 12 to 15 years received the same dosage as adults.

The companies recently began testing the vaccine in children ages 6 months to 11 years.

Moderna started a study of its vaccine in 12- to 17-year-olds last year and expects results sometime this spring. The company in March started a separate trial of the vaccine in children under 12.

Early this month, Johnson & Johnson said it began testing its Covid-19 vaccine in youths 12 to 17 years.

Thomas M. Burton and Peter Loftus contributed to this article.





Write to Jared S. Hopkins at jared.hopkins@wsj.com

(END) Dow Jones Newswires

04-09-21 1458ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 10.15% 202.35 Delayed Quote.125.36%
DJ INDUSTRIAL -0.10% 34742.82 Delayed Quote.13.63%
MODERNA, INC. -2.82% 158.55 Delayed Quote.56.17%
PFIZER, INC. 0.71% 39.86 Delayed Quote.7.53%
All news about BIONTECH SE
05:23pU.S. authorizes Pfizer/BioNTech COVID vaccine for children 12 to 15
04:25pHealth Care Climbs On Rotation Into Value -- Health Care Roundup
04:00pFirst Covid-19 Vaccine Cleared for U.S. Adolescents -- Update
03:39pKIDS AND THE COVID-19 VACCINEá : Is it Safe and When Can They Get It?
03:38pFDA Authorizes Pfizer-BioNTech Covid-19 Vaccine for 12- to 15-Year-Olds
03:17pBIONTECHá : Germany's BioNTech Picks Singapore for Southeast Asia HQ, Plans New ..
02:13pBIONTECHá : to Lift COVID-19 Vaccine Output, Expand Drug Pipeline and Global Bas..
12:44pU.S. FDA advisory panel to meet on COVID-19 vaccines in children
12:21pEUROPE : European stocks end at record highs as miners rally
12:20pEuropean Stocks End Mixed Amid BioNTech, Provident Financial Quarterly Report..
More news
Sales 2021 9 519 M 11 551 M 11 551 M
Net income 2021 5 747 M 6 973 M 6 973 M
Net cash 2021 6 515 M 7 906 M 7 906 M
P/E ratio 2021 9,08x
Yield 2021 -
Capitalization 44 370 M 44 370 M 53 841 M
EV / Sales 2021 3,98x
EV / Sales 2022 5,48x
Nbr of Employees 1 941
Free-Float 87,3%
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 111,11 €
Last Close Price 202,35 €
Spread / Highest target -13,4%
Spread / Average Target -45,1%
Spread / Lowest Target -56,2%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Sierk P÷tting Chief Operating & Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE125.36%44 370
WUXI APPTEC CO., LTD.6.21%54 226
BEIGENE, LTD.20.74%28 740